Skip to main content
Signal8

Erasca, Inc. (ERAS)

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Erasca, Inc. logo

Erasca, Inc.

NASDAQ:ERASHealthcare
Pre+0.62%$14.50
Close$14.41+8.59%AH$14.57-0.48%since
Mkt Cap$5.04B
Float254.49M
O/S349.76M
PM VOL4K sh
$ Vol≈$52K
RVOL0.47×
Inst Own81.4%
SI14.5%
Dilution
Erasca, Inc. logoNASDAQ:ERASPre$14.50+0.62%
Historical Data
DateOpenHighLowCloseVolume
Nov 6, 202613.4214.4313.1114.414,032,172
Nov 5, 202614.9115.1813.1713.276,689,769
Nov 4, 202615.0915.1314.1814.913,501,513
Nov 3, 202614.3015.0014.0614.643,798,385
Nov 2, 202614.7615.3813.7214.054,428,188
Oct 30, 202614.6615.0114.0414.353,749,485
Oct 29, 202615.1115.4514.6614.982,280,743
Oct 28, 202614.9015.3214.4515.123,412,302
Oct 27, 202614.9515.2614.7215.225,825,748
Oct 26, 202614.5815.4714.5414.996,466,123
Oct 23, 202613.9914.4513.4414.393,499,957
Oct 22, 202614.2214.6413.8114.042,296,073
Oct 21, 202614.8215.0514.3814.493,845,039
Oct 20, 202613.4014.9713.1014.624,218,225
Oct 19, 202613.7313.9813.3413.624,263,888
Oct 16, 202614.8714.8713.2713.397,089,287
Oct 15, 202614.7115.2614.3614.878,481,042
Oct 14, 202614.4115.0814.2914.704,747,561
Oct 13, 202615.2515.5814.5014.785,313,582
Oct 12, 202615.8816.0115.3215.464,280,360
Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target (median, last 90d)
$21.50+49.2%
Low $21High $22
Ratings Distribution
BUY
9
HOLD
2
SELL
0
TOTAL11
Insider Trades
InsiderTypeShares
Fuchs Charles S. profile photoFuchs Charles S.Grant/Award1.30M
Start Valerie Denise Harding profile photoStart Valerie Denise HardingGrant/Award29.9K
Bristol James Arthur profile photoBristol James ArthurGrant/Award29.9K
Hambleton Julie profile photoHambleton JulieGrant/Award29.9K
Casdin Alexander W. profile photoCasdin Alexander W.Grant/Award29.9K
Multani Pratik S profile photoMultani Pratik SGrant/Award29.9K
Shareholders
81.4%
Institutional
(263)
0.1%
Insiderⓘ
(3)
11.5%
5%+ Owners
(3)
of which 3.7% rests on schedules older than 24 months (1 holder)
7.0%
Unattributed (incl. retail)ⓘ
Institutional81.4%
Insider0.1%
5%+ Beneficial11.5%
Unattributed (incl. retail)7.0%
Sources: 13F, Form 4, 13D/13GO/S: 349.8M · as of 4 Aug 2026 · SEC cover page
Insiders & Institutional Holders

Insiders

Top institutional holders

About

Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway.

The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors.

Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme.

The company was founded in 2018 and maintains its headquarters in San Diego, California.

Key Metrics
Market Cap$5.04B
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership81.40%

based on 349.76M shares outstanding

SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
CountryUSUS
IPO DateJul 16, 2021
Shares Outstanding349.76M
Authorized Shares
Float254.49M
52-Week Range
$2.10$24.28
$14.41(55th percentile)
Volume
Average Daily Volume4.61M
4.03M today vs 4.61M avg(-13%)

30d Avg

4.61M

60d Avg

4.92M

90d Avg

4.54M

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...